Pangenomic Health Inc.
NARA
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 188.80K | 263.40K | 371.90K | 505.50K | 599.10K |
| Gross Profit | -188.80K | -263.40K | -371.90K | -505.50K | -599.10K |
| SG&A Expenses | 606.60K | 666.20K | 997.00K | 1.32M | 1.54M |
| Depreciation & Amortization | 8.40K | 9.20K | 9.20K | 9.10K | 9.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 815.00K | 949.20K | 1.43M | 2.02M | 2.36M |
| Operating Income | -815.00K | -949.20K | -1.43M | -2.02M | -2.36M |
| Income Before Tax | -2.57M | -2.72M | -1.58M | -2.20M | -8.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.57 | -2.72 | -1.58 | -2.20 | -8.70 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.57M | -2.72M | -1.58M | -2.20M | -8.70M |
| EBIT | -815.00K | -949.20K | -1.43M | -2.02M | -2.36M |
| EBITDA | -806.50K | -939.90K | -1.42M | -2.01M | -2.35M |
| EPS Basic | -0.63 | -0.76 | -0.79 | -1.11 | -5.35 |
| Normalized Basic EPS | -0.21 | -0.29 | -0.49 | -0.69 | -0.86 |
| EPS Diluted | -0.63 | -0.76 | -0.79 | -1.11 | -5.35 |
| Normalized Diluted EPS | -0.21 | -0.29 | -0.49 | -0.69 | -0.86 |
| Average Basic Shares Outstanding | 16.14M | 11.73M | 8.12M | 8.00M | 7.50M |
| Average Diluted Shares Outstanding | 16.14M | 11.73M | 8.12M | 8.00M | 7.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |